Somaxon Pharmaceuticals Inc

Somaxon Pharmaceuticals — Investor Presentation (April 2006)

20 slides from Somaxon Pharmaceuticals's investor presentation, Apr 11, 2006

  1. Slide 1: Specialty Pharmaceuticals for Psychiatry & Neurology

    Specialty Pharmaceuticals for Psychiatry & Neurology NASDAQ: SOMX

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements about our business, including results of our clinical trials, potential indications for our product candidates, development timelines, future financial results and events that have not yet occurred. Pharmaceutical devel

  3. Slide 3: Highlights

    Highlights Specialty pharmaceuticals focused on psychiatric and neurologic disorders Three in-licensed product candidates with extensive human experience & established safety records Highly differentiated product profiles addressing large markets Positive Phase 3 data for unique, non-scheduled drug

  4. Slide 4: Pipeline

    Pipeline SILENOR(tm) - Insomnia Nalmefene - Impulse Control Disorders Acamprosate Movement Disorders Pre- Clinical Phase 1 Phase 2 Phase 3 Nalmefene - Smoking Cessation

  5. Slide 5: Insomnia Market Growth

    Insomnia Market Growth 2001 2002 2003 2004 2005 East 1.3 1.8 2.2 2.7 3.3 Total Dollars Billions $1.3 $1.8 $2.2 $2.7 $3.3

  6. Slide 6: SILENOR (doxepin HCl) for Insomnia

    SILENOR(tm)(doxepin HCl) for Insomnia Tricyclic compound approved >35 years as an antidepressant Long term safety record with chronic usage At high doses, a range of pharmacologic activities Potent H1 antagonism believed to cause sedation No GABA effects

  7. Slide 7: SILENOR vs GABA acting drugs

    "Doxepin HCl is virtually devoid of euphoria as a side effect. Characteristic of this type of compound, doxepin HCl has not been demonstrated to produce the physical tolerance or psychological dependence associated with addictive compounds." SILENOR(tm) vs GABA acting drugs "LUNESTA is a Schedule IV

  8. Slide 8: Daily Dosage (mg)

    Daily Dosage (mg) 10 25 50 75 300 Depression Available strengths too sedating & anticholinergic Two issued US patents claiming treatment of insomnia at low dose Generics cannot offer dosages below 10mg nor insomnia claims Market prefers not to alter dosage forms, especially across indications 1 6 In

  9. Slide 9: Phase 3 Adult Study Design

    Phase 3 Adult Study Design Randomized, placebo controlled, double blind, parallel group, multicenter, sleep laboratory (PSG) and outpatient study 229 adults with chronic primary sleep maintenance insomnia based on history & PSG screening Placebo, 3mg and 6mg dosages Efficacy endpoints Primary: PSG-m

  10. Slide 10: Phase 3 Adult Trial, Primary Endpoint Wake After Sleep Onset

    Phase 3 Adult Trial, Primary Endpoint Wake After Sleep Onset (WASO) (ITT) PBO DXP 3 mg DXP 6 mg ITT 66.7 41.4 36.3 Minutes (mean) p<0.0001 p<0.0001

  11. Slide 11: Phase 3 Adult Trial Wake After Sleep Onset, Baseline to Night 29

    PBO DXP 3mg DXP 6mg Baseline 65.6 67.8 65 N1 66.7 41.4 36.3 N15 60.7 44.8 41.9 N29 61.8 47.3 41.2 Minutes Nights Phase 3 Adult Trial Wake After Sleep Onset (WASO) Baseline to Night 29 (ITT) p<0.0001 p<0.0001 P=0.0053 P=0.0023 P=0.0299 P=0.0012

  12. Slide 12: Phase 3 Adult Trial Total Sleep Time

    Phase 3 Adult Trial Total Sleep Time (TST) (ITT) PBO DXP 3 mg DXP 6 mg ITT 373.8 415.3 420.5 Minutes (mean) p<0.0001 p<0.0001

  13. Slide 13: Phase 3 Adult Trial Efficacy Summary

    Phase 3 Adult Trial Efficacy Summary Primary endpoint (WASO) significant at all time points for all doses Significant effects on sleep maintenance for 3 mg and 6 mg (WASO, WTDS, WTAS, TST, SE) WASO, WTDS, TST, SE sustained for up to 4 weeks LPS significant first night on drug; placebo response obser

  14. Slide 14: Phase 3 Adult Trial Safety & Tolerability Summary

    Phase 3 Adult Trial Safety & tolerability summary No Tolerance - improvement from baseline sustained at all time points Sleep Stages preserved No significant effects on Next Day Residual Sedation No Rebound Insomnia No Withdrawal Effects Well Tolerated - low discontinuation rate AE Profile similar t

  15. Slide 15: Positioning Targeted by Phase III

    Positioning Targeted by Phase III Amnesia Euphoria Hormone Changes Metallic Taste Attributes Sonata Ambien Ambien CR Lunesta Indiplon Rozerem SILENORTM Onset Maintenance Last 3rd of Night Long Term Studies Not Scheduled Not GABA

  16. Slide 16: Clinical Development Plan

    Clinical Development Plan Ph 3 Transient 2005 2006 2007 Ph 3 Adult PSG Ph 1 PK Studies Ph 3 Elderly PSG Ph 3 Elderly Outpatient NDA Filing

  17. Slide 17: Experienced Management

    Experienced Management Kenneth Cohen Kenneth Cohen President & CEO Philip Jochelson, MD Philip Jochelson, MD SVP & CMO Meg McGilley Meg McGilley VP & CFO Jeff Raser Jeff Raser SVP Sales & Marketing Susan Dube Susan Dube SVP Corporate Development Eli Lilly, Argus, Canji Boehringer Ingelheim, Alliance

  18. Slide 18: Financial Highlights

    Financial Highlights NASDAQ: SOMX Cash, cash equivalents & short term investments, 12/31/05 Cash burn, LTM 12/31/05 Shares outstanding, 12/31/05 Fully diluted shares, 12/31/05 $104 mm $23.7 mm 18.0 mm 19.4 mm

  19. Slide 19: Key milestones

    Key milestones SILENOR(tm) Phase 3 adult results - Q2 '06 ^ Phase 3 elderly results - late '06 Phase 3 transient results - late '06 Phase 3 elderly outpatient results - late '06 NDA - Q1 '07 Strategic partnership Nalmefene Pilot smoking cessation results - mid '06 Phase 2/3 PG results - early '07

  20. Slide 20: Highlights

    Highlights Specialty pharmaceuticals focused on psychiatric and neurological disorders Three in-licensed product candidates with extensive human experience & established safety records Highly differentiated product profiles addressing large markets Positive Phase 3 data for unique, non-scheduled dru

Somaxon Pharmaceuticals — Investor Presentation (April 2006) on 6ix